Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of specific share transactions and does not contain financial performance data.
Material Changes
The filing reports an increase in the notional allocation of GSK American Depositary Shares (ADSs) on January 16, 2015. This change resulted from the revaluation of the cash element of the notional investment held within the GSK 401K plan. The transaction price was $43.70 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific director and connected person transactions listed below.
Important Facts for Investors
- Transaction Date: January 16, 2015 (Advised on January 19, 2015).
- Transaction Price: $43.70 per ADS.
- Director Transaction: Dr. M. M. Slaoui received an increase of 21 ADSs.
- Connected Person Transaction: Dr. K. Slaoui (connected person of Dr. M. M. Slaoui) received an increase of 4 ADSs.
- Reason for Change: Revaluation of the cash element within the GSK 401K plan.